Feb 07th 2013 - Edison Investment Research today published a report on Allocate Software (ALL.L, LSE:ALL, LON:ALL) entitled "Prospects Remain Positive". In summary, the report says:
While sales growth stalled in H1, we feel that the transition to a more subscription weighted model was the main factor behind this. With the launch of HealthRoster V10 and Cloud providing fresh sales impetus, the NHS renewal cycle gathering steam and the recurring revenue base growing, we expect growth to resume from here. We believe the current rating captures neither the strength of Allocate’s position in the NHS, nor the progress made in moving to a more attractive recurring revenue model.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »